A small, implantable device being designed to deliver extended-release pain medicine aims to ensure patient compliance and stymie opiate abuse. Axxia Pharmaceuticals is developing an implant the size and shape of a shirt button that can subcutaneously deliver an opiate for 30 to 90 days without any moving parts. The first application of the technology will deliver hydromorphone for treatment of moderate to severe chronic pain in cancer patients.
